<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reactive oxygen species (ROS) have an established role in <z:mp ids='MP_0001845'>inflammation</z:mp> and host defense, as they kill intracellular bacteria and have been shown to activate the NLRP3 inflammasome </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we find that ROS generated by <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> respiration are important for <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS)-driven production of several proinflammatory cytokines and for the enhanced responsiveness to LPS seen in cells from patients with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e>), an autoinflammatory disorder caused by missense mutations in the type 1 TNF receptor (TNFR1) </plain></SENT>
<SENT sid="2" pm="."><plain>We find elevated baseline ROS in both mouse embryonic fibroblasts and human immune cells harboring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e>-associated TNFR1 mutations </plain></SENT>
<SENT sid="3" pm="."><plain>A variety of <z:chebi fb="11" ids="22586">antioxidants</z:chebi> dampen LPS-induced MAPK phosphorylation and inflammatory cytokine production </plain></SENT>
<SENT sid="4" pm="."><plain>However, gp91(phox) and p22(phox) <z:chebi fb="0" ids="16474">reduced nicotinamide adenine dinucleotide phosphate</z:chebi> (<z:chebi fb="1" ids="16474">NADPH</z:chebi>) oxidase subunits are dispensable for inflammatory cytokine production, indicating that <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidases are not the source of proinflammatory ROS </plain></SENT>
<SENT sid="5" pm="."><plain>TNFR1 mutant cells exhibit altered <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function with enhanced oxidative capacity and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS generation, and pharmacological blockade of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS efficiently reduces inflammatory cytokine production after LPS stimulation in cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e> patients and healthy controls </plain></SENT>
<SENT sid="6" pm="."><plain>These findings suggest that <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS may be a novel therapeutic target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TRAPS</z:e> and other <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> </plain></SENT>
</text></document>